NEW YORK (GenomeWeb News) – Life Technologies today announced a commercialization deal covering three stem cell technologies from Cellular Dynamics International for the consistent development and growth of human iPS cells for research and bioproduction.

Life Tech will commercialize CDI's Essential 8 Medium, Vitronectin, and Episomal iPSC Reprogramming Vectors, which together address several challenges associated with developing relevant cells, the Carlsbad, Calif.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.